Drugs / LY3475766
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04052594 | Sep 2019 → Mar 2021 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3475766 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04052594 ↗ |
| Action | Inhibit | “specifically blocks ANGPTL3/8-mediated inhibition of LPL activity” PMID 40640392 ↗ Jul 2025 |
| Modality | Monoclonal antibody | “LY3475766, a human monoclonal antibody” PMID 40640392 ↗ Jul 2025 |
| Route | Intravenous | “Administered IV” NCT04052594 ↗ |
| Target | ANGPTL3 | “a human monoclonal antibody that specifically blocks ANGPTL3/8-mediated inhibition of LPL activity” PMID 40640392 ↗ Jul 2025 |